CD19-Directed CAR T-Cell Therapy Is Feasible in Patients over 65 Years of Age in Outpatient Setting

Moving CAR‐Ts to the outpatient clinic

“…The outpatient treatment strategy proved to be feasible and resulted in shorter hospitalization time. 1 Given the increasing integration of CAR T-cell therapy to treatment algorithms for relapsed/refractory B-cell malignancies, outpatient administration represents an appealing approach beneficial to both patients and health care institutions. However, a well-established, multidisciplinary care infrastructure with specially trained providers, allocated resources and optimal patient selection is needed to successfully deliver CAR T-cell therapies in this setting.…”

“…Most patients received axicabtagene ciloleucel; remaining patients were given tisagenlecleucel and brexucabtagene autoleucel. The outpatient treatment strategy proved to be feasible and resulted in shorter hospitalization time 1 . Given the increasing integration of CAR T‐cell therapy to treatment algorithms for relapsed/refractory B‐cell malignancies, outpatient administration represents an appealing approach beneficial to both patients and health care institutions.…”